Invitation only event
Join experts from the University of Cambridge, AstraZeneca and GSK to discuss safety challenges of adverse events resulting from drugs that modulate the immune system. Expected outcomes are potential future research and recommendations on best practice.
Morning session will include presentations to set the scene
Humanised mouse models for assessment of safety and efficacy of immunotherapies: Opportunities and challenges. Mr Kourosh Saeb-Parsy, University of Cambridge, Cambridge University Hospitals
Tweaking Innate Immunity: a therapeutic opportunity or an adverse event nightmare in waiting? Professor Clare Bryant, University of Cambridge
Learning about Immunotherapy toxicity and mechanisms in rare-patients and mouse models. Dr James Thaventhiran, MRC Toxicology Unit, University of Cambridge.
Afternoon session will involve break-out sessions and delegates are invited to provide a preference for which discussion group they would like to join
Workshop 1: The benefits and drawbacks of humanised mice in the understanding of immunotoxicological events in drug development
Workshop 2: Modelling immune related adverse events (irAEs) in preclinical species and with ex vivo human tissues; how to predict IO-related adverse events in patients.
Workshop 3: When does activation of the innate immune response, or inhibition of innate immunity, become adverse?
This event includes lunchtime refreshments and a poster session.
